CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: December 18, 2020
Result type: Reports
Project Number: SR0641-000
Product Line: Reimbursement Review

Generic Name: fremanezumab

Brand Name: Ajovy

Manufacturer: Teva Canada Innovation

Therapeutic Area: migraine

Indications: ​Indicated for the prevention of migraine in adults who have at least 4 migraine days per month.

Manufacturer Requested Reimbursement Criteria1: For the prevention of migraine in adults who have at least 4 migraine days per month.

Submission Type: Initial

NOC Status at Filing: Post NOC

Project Status: Active

Companion Diagnostics: No

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input openMarch 30, 2020
Call for patient input closedMay 20, 2020

- Patient input submission received from Migraine Canada and Migraine Quebec

Submission receivedJune 03, 2020
Submission acceptedSeptember 22, 2020

- Submission was not accepted for review on 17 June 2020

Review initiatedSeptember 23, 2020
Draft CADTH review report(s) provided to sponsor for commentDecember 18, 2020
Deadline for sponsors commentsJanuary 06, 2021
CADTH responses on draft review report(s) provided to sponsorFebruary 04, 2021
Expert committee meeting (initial)February 17, 2021
Draft recommendation issued to sponsorMarch 01, 2021
March 03, 2021